Precision Neuroscience

Precision Neuroscience is pursuing a distinct engineering point in the BCI design space: high-channel-count cortical surface sensing with a thin, conformal film that can be placed on the brain surface rather than penetrating into cortex.

Their core device is the Layer 7 Cortical Interface — a high-density electrode array embedded in a flexible film intended for recording/monitoring (and, per their regulatory clearance/press coverage, stimulation) of cortical activity.

Company background

• Website: ⁰¹
• About page (company narrative + leadership): ⁰²
• Headquarters: New York City (per press coverage; confirm on LinkedIn later if we want a consistent data source).

• Funding (Sep 24, 2026): Precision closed an oversubscribed $250M Series D co-led by Pershing Square and the Ackman Oxman Institute, bringing total capital raised to $430M, and reports more than 100 patient procedures across 18 medical institutions. Source: ⁰³

The technology: Layer 7 Cortical Interface

Public descriptions emphasize:

• Cortical surface interface (non-penetrating)
• Thin-film flexible array designed to conform to the brain surface
• High electrode count: commonly reported as 1,024 electrodes

Secondary reporting (MassDevice) describes the Layer 7 device as:

• 1,024 electrodes embedded in a flexible film

• thinness on the order of ~one-fifth the thickness of a human hair (journalistic paraphrase of company claims)

• MassDevice (Apr 17, 2025): ⁰⁴

Precision’s own framing is explicit about the design goal:

“a high-bandwidth connection to the brain that did not rely on penetrating electrodes”

• Precision “About”: ⁰²

Regulatory status (key differentiator)

Precision reports that it received an FDA 510(k) clearance in 2025 for the Layer 7 Cortical Interface.

• Precision “About” (mentions first FDA clearance in 2025): ⁰²

Multiple outlets report this as FDA 510(k) clearance and note a commercially-cleared use case window up to 30 days implantation.

• Press release (GlobeNewswire, Apr 17, 2025): ⁰⁵
• MassDevice coverage (Apr 17, 2025): ⁰⁴

Primary regulatory document (510(k) letter/summary PDF):

• FDA 510(k) document (K242618): ⁰⁶

Why this approach is interesting (and what to watch)

1) Minimally invasive doesn’t mean “easy,” but it changes the risk profile

A surface array avoids penetrating tissue and may reduce certain risks (e.g., insertion trauma), but it still lives in a surgical environment with constraints around stability, infection, and long-term biocompatibility.

2) Surface recordings: bandwidth vs spatial specificity

High-density surface electrodes can offer rich signals, but the spatial selectivity differs from intracortical spikes. This makes algorithm+hardware co-design central: what do you decode, from which signal features, under what motion/noise conditions?

3) Clinical workflow matters

One of the more practical near-term wedges is intraoperative mapping (explicitly mentioned in reporting). That path pressures the system to be useful quickly, with neurosurgical-friendly setup time, robust connectors, and clean data plumbing.

• MassDevice notes intraoperative mapping as a clinical marketing path post-clearance: ⁰⁴

4) “Removable” and “up to 30 days” are big claims — watch the details

A surface interface that is both high-density and safely removable (and has a cleared temporary implant window) is a meaningful engineering milestone. The details that will matter:

• what the cleared indications actually are
• what “up to 30 days” means in practice (patient selection, monitoring, adverse event profile)
• signal quality drift over days/weeks

Primary reference for the clearance details:

• FDA K242618 document: ⁰⁶

Company notes (from Precision)

Precision’s own history highlights:

• founded/started work in 2021

• leadership includes co-founder Ben Rapoport (MD, PhD)

• claims of owning/operating manufacturing capacity via acquiring a microfabrication facility (Precision BioMEMS)

• FDA Breakthrough Designation (2023) and FDA 510(k) Clearance (2025)

• Precision “About”: ⁰²

atlas manuscript

• Atlas (company claim): Precision announced a manuscript, available on bioRxiv, describing a growing atlas of the human central nervous system. It is built from high-resolution surface electrophysiology recordings in 70 patients across twelve academic medical centers, with more than 100,000 electrode deployments, more than 180 hours of synchronized neural and behavioral data, and 87,342 individual microelectrodes (all per the company release). Recordings were made with the Layer 7 Cortical Interface, described as up to 1,024 channels at 400-micron pitch.
• Implant count (company claim): the release says the total number of patients implanted with the Precision system “has now surpassed 100.” The Sep 24 release above gives the same figure as more than 100 patient procedures across 18 medical institutions.
• The manuscript itself has not been read for this brief; the figures above come from the press release only.
• Source: ⁰⁷

leadership appointments

• Leadership (Oct 15, 2026, company press release): Konstantinos Alataris, founder and former CEO of Nevro and a Precision board member since May 2025, joined as president. Katherine Neuenfeldt, who led the U.S. launch and market access strategy for Nevro’s Senza spinal cord stimulation system, joined as senior vice president, commercial strategies. The release frames both hires around commercialization and reimbursement following the Series D. Source: ⁰⁸
• Valuation (reported, not confirmed by the company): The New York Times reported the Series D valued Precision at about $1 billion, per The Next Web (Sep 24, 2026). Neither company release used here states a valuation. Source: ⁰⁹